ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Ghent, Belgium, 28 June 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, today announced it has been awarded a two-year R&D grant of EUR 1.6 million by Flanders Innovation & Entrepreneurship (VLAIO) for pre-clinical research towards prophylactic and therapeutic solutions for dengue.
